Paragon 28, Inc.

General Information
Business:

We are a leading medical device company exclusively focused on the foot and ankle orthopedic market and we are dedicated to improving patient lives. Our innovative orthopedic solutions, procedural approaches and instrumentation cover a wide range of foot and ankle ailments, including fracture fixation, hallux valgus (bunions), hammertoe, progressive collapsing foot deformity (PCFD) or flat foot, and charcot foot. To treat these painful, debilitating or even life-threatening conditions, we provide a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. Our broad suite of surgical solutions comprises 72 product systems, including approximately 8,700 SKUs to help fit the specific needs of each patient and procedure. We design each of our products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent and reproducible.

(Note: Paragon 28, Inc. priced its IPO on Oct. 14, 2021, at $16 – the mid-point of its $15-to-$17 price range – on 7.81 million shares, the same number of shares in the prospectus, to raise $124.96 million.)

Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees: 295
Founded: 2010
Contact Information
Address 14445 Grasslands Drive, Englewood, CO 80112, US
Phone Number (730) 399-3400
Web Address http://www.paragon28.com
View Prospectus: Paragon 28, Inc.
Financial Information
Market Cap $1203.2mil
Revenues $134.2 mil (last 12 months)
Net Income $2.39 mil (last 12 months)
IPO Profile
Symbol FNA
Exchange NYSE
Shares (millions): 7.8
Price range $16.00 - $16.00
Est. $ Volume $125.0 mil
Manager / Joint Managers BofA Securities/ Piper Sandler
CO-Managers Canaccord Genuity/ JMP Securities/ Needham & Company
Expected To Trade: 10/15/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change